|
MAMBISA Study |
26/11/2020 |
CIGB |
|
VISION Study |
26/10/2021 |
CIGB |
|
Itolizumab Safety and Efficacy Study in Covid 19 |
26/03/2021 |
CIM |
|
ESAR-814 Study |
26/01/2017 |
CIGB |
|
Efficacy and safety of Jusvinza treatment in patients with acute respiratory distress syndrome. Phase II/III |
24/04/2023 |
CIGB |
|
CIMAvax®-EGF in patients with moderate-severe chronic obstructive pulmonary disease (COPD) |
24/03/2025 |
CIM |
|
Effect of beef consumption on lipid metabolism |
23/08/2019 |
SSA |
|
SOBERANA CENTRO |
23/07/2021 |
FINLAY |
|
CIGB-500 in acute myocardial infarction (AMIGOS study) |
23/04/2014 |
CIGB |
|
EGF in bilateral symmetric diabetic neuropathy |
23/03/2020 |
CIGB |
|
Bioequivalence of Efavirenz |
22/12/2017 |
CIDEM |
|
CIMAvax-EGF in patients at high risk of lung cancer |
22/10/2020 |
CIM |
|
NeuroEPO in mild-moderate Alzheimer's disease amnesic variant |
22/09/2022 |
CIM |
|
Safety and effect of Itolizumab in extracorporeal circulation, phase I/II |
22/08/2024 |
CIM |
|
Safety and efficacy of CIMAvax®-EGF in combination with tyrosine kinase inhibitors in patients with advanced stage Non-Small Cell Lung Cancer and EGFR mutations |
22/05/2021 |
CIM |
|
Abexol (suspension) versus Abexol (tablets) in patients with gastrointestinal symptoms |
22/05/2021 |
CPN |
|
Itolizumab for Relapsing Remitting Multiple Sclerosis |
22/05/2015 |
CIM |
|
Safety and pharmacokinetics of CIGB-552 |
22/05/2015 |
CIGB |
|
Phase II-III clinical trial to evaluate the vaccine candidate against pneumococcal diseases VCN11 in infants |
21/08/2024 |
FINLAY |
|
Safety of Orally Administered Neutral pH Super Oxidation Electrolyzed Solution |
21/07/2023 |
SSA |
